National Patient Safety Foundation

Process mapping of a collaborative quality improvement study to optimise the use of antibiotics in intensive care units in Argentina: a Pathfinder study

<ns5:p>Objective To systematically document the operational components, barriers, facilitators, and solutions of a quality improvement collaborative for antibiotic stewardship in intensive care units (ICUs) in the public sector of Argentina, using the Pathfinder methodological fr...

Beyond ‘diagnostic error’: an ethnography of resilient behaviours and system adaptations in paediatric outpatient diagnosis

Background Improving paediatric diagnosis by addressing errors (Safety-I) is insufficient for diagnostic excellence. Resilience engineering’s approach to understanding adaptations to achieve success in everyday work may elucidate how individuals and systems manage diagnostic comp...

Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective

ABSTRACT Primary biliary cholangitis (PBC) is an autoimmune liver disease that targets the small intrahepatic bile ducts with diagnosis based on elevated serum alkaline phosphatase (ALP) levels and the presence of anti‐mitochondrial antibodies. Untreated, it may run a progressive...

Inpatient Use of Continuous Glucose Monitors: Insights From Pennsylvania Patient Safety Event Reports

Introduction Inpatient use of continuous glucose monitors (CGMs) has historically been prohibited. Increased outpatient use, critical needs during the COVID-19 pandemic, and growing interest in allowing use of CGMs to manage blood glucose levels for hospitalized patients have pro...

Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland

AIMS: KEYNOTE-689 trial results demonstrated that neoadjuvant pembrolizumab followed by adjuvant pembrolizumab plus standard of care (NP/AP + SOC) significantly improved event-free survival (EFS) versus SOC alone in patients with locoregionally advanced head and neck squamous cel...